target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,hexamethonium,3963,,3604,C[N+](CCCCCC[N+](C)(C)C)(C)C,"InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2",VZJFGSRCJCXDSG-UHFFFAOYSA-N,Channel blocker,None,,,,,,,,,,,,,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,[125I]epibatidine,3976,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β4,,,,pKd,,10.38,,Kd,,0.042,,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,P12389,Rat,[125I]epibatidine,3976,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β2,,,,pKd,11.0,,10.68,Kd,0.021,,0.01,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,P12389,Rat,[125I]epibatidine,3976,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β4,,,,pKd,10.08,,10.06,Kd,0.087,,0.084,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,[3H]epibatidine,3977,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β4,,,,pKd,,10.38,,Kd,,0.042,,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,P12389,Rat,[3H]epibatidine,3977,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β2,,,,pKd,11.0,,10.68,Kd,0.021,,0.01,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,P12389,Rat,[3H]epibatidine,3977,,1204,Clc1ccc(cn1)C1CC2NC1CC2,"InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2",NLPRAJRHRHZCQQ-UHFFFAOYSA-N,Agonist,Full agonist,α2β4,,,,pKd,10.08,,10.06,Kd,0.087,,0.084,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,[3H]cytisine,3979,,53321937,c1([3H])cc([3H])c(=O)n2c1[C@H]1CNC[C@H](C1)C2,"InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1/i2T,3T",ANJTVLIZGCUXLD-ZIAKYUPESA-N,Agonist,Full agonist,,,,,,,,,,,,,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,mecamylamine,3990,,4032,CNC1(C)C2CCC(C1(C)C)C2,"InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3",IMYZQPCYWPFTAG-UHFFFAOYSA-N,Channel blocker,None,,,,,,,,,,,,,=,,,,, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,LY2087101,3992,,11964458,Fc1ccc(cc1)Nc1nc(c(s1)C(=O)c1cscc1)C,"InChI=1S/C15H11FN2OS2/c1-9-14(13(19)10-6-7-20-8-10)21-15(17-9)18-12-4-2-11(16)3-5-12/h2-8H,1H3,(H,17,18)",PEAMDZVDNYENPN-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,,,,,,,,,=,,,,16738207, nicotinic acetylcholine receptor α2 subunit,463,Q15822,Human,CP-601927,9056,,11498153,FC(c1ccc2c(c1)[C@H]1CNC[C@@H]2C1)(F)F,"InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1",RNOBTWYQAWEZHH-JGVFFNPUSA-N,Agonist,Partial agonist,,,yes,,pKi,,8.92,,Ki,,1.2,,=,Measured against α2β4 nAchRs- species not identified.,,,21566524,